Japan Alzheimer's Disease - Epidemiology Forecast - 2032

This ‘Alzheimer's Disease - Japan Epidemiology Forecast - 2032' report delivers an in-depth understanding of Alzheimer's disease, historical and forecasted epidemiology, and the trends in Japan.

Alzheimer's Disease Understanding

Alzheimer's disease, the most common type of dementia, is a progressive neurodegenerative disorder with a multifactorial pathogenesis. It is characterized by the gradual decline in cognitive and functional abilities, with individuals eventually losing the ability to undertake everyday tasks and function independently. Symptoms, for most people, first appear in their mid-60s; however, early disease may also manifest in quadragenarians.

Although the symptoms vary widely, they develop slowly and worsen over time. Early signs may include forgetfulness, difficulty with problem-solving or completing familiar tasks, confusion, disorientation, and changes in mood or behavior. As the disease progresses, individuals may experience severe memory loss, language problems, impaired judgment, personality changes, and a decline in overall cognitive abilities.

Improved disease understanding demonstrates that the disease is characterized by two microscopic features, amyloid plaques and neurofibrillary agglomerates. The exact cause is mostly unknown, but research indicates that progressive cognitive decline is associated with the accumulation of amyloid-beta (Aß) and tau proteins. These deposits form amyloid protein plaques outside the brain cells and tangles of tau protein within the brain cells.

These plaques and tangles disrupt normal communication between brain cells, leading to progressive degeneration, memory deterioration, and death. Increasing age and family history are important risk factors.

The disease progresses through several stages with a corresponding increase in severity. The preclinical stage is mostly asymptomatic, while in the next mild cognitive impairment stage, an individual may experience mild memory problems, but this may not significantly affect daily functioning, and some individuals with MCI may not progress to Alzheimer's disease. Mild, moderate, and severe stages are associated with progressive deterioration of memory that affects language, personality, or cognitive control, with symptoms interfering with daily life. Mild Alzheimer's disease is when symptoms start interfering with daily life. Further, moderate Alzheimer's disease can last for years, making symptoms more pronounced and assistance with daily activities necessary. In the last stage, i.e., severe Alzheimer's disease, individuals lose the ability to communicate verbally, recognize their loved ones, and carry out basic tasks. The risk of infections and other complications increases, leading to a further decline in health.

Alzheimer's Disease Diagnosis

The pathogenesis is multifactorial, and due to the continuous discovery of novel signaling pathways, various diagnostic tools have revolutionized and improved disease diagnosis, making it more personalized. This has helped in understanding the various possibilities of tau and amyloid deposition, neurodegeneration, and symptom manifestation.

Diagnosing Alzheimer's disease involves a comprehensive evaluation of medical history, cognitive tests, neurological exams, and assessment of behavioral and functional changes. There is no single test for the diagnosis. Clinical practice typically diagnoses it through a multidisciplinary workup based on patient history, clinical symptoms, and neuropsychiatric, physical, and functional assessments. Imaging (computed tomography, magnetic resonance imaging (MRI), positron emission tomography (PET) assessments, and blood tests are particularly important to rule out certain other causes of dementia. PET scans, especially amyloid scans, fluorodeoxyglucose imaging, and tau imaging, besides CSF biomarkers and blood-biomarker-based diagnosis, have improved the diagnosis manifold
Standardized tests such as the Mini-Mental State Examination (MMSE) or the Montreal Cognitive Assessment (MoCA) are commonly used for cognitive and functional assessment. The diagnostic guideline provided by the National Institute on Aging (NIA), called NIA-AA criteria, is the most accepted.

Earlier diagnosis of Alzheimer's disease is important to enable symptomatic therapies, treat behavioral symptoms, and adopt lifestyle changes that are used more commonly worldwide to reduce the risk of developing dementia and, eventually, to slow disease progression.

Alzheimer's Disease Epidemiology Perspective

The disease epidemiology covered in the report provides historical and forecasted epidemiology segmented by total diagnosed prevalent cases of Alzheimer's disease, gender-specific cases of Alzheimer's disease, age-specific cases of Alzheimer's disease, and severity-specific cases of Alzheimer's disease in Japan from 2019 to 2032.

Alzheimer's Disease Detailed Epidemiology Segmentation

• In 2022, the total diagnosed prevalent cases of Alzheimer's disease in Japan were estimated to be approximately 3,954,710. These cases are projected to increase during the forecast period.
• As per the report estimates, Alzheimer's disease is more common in females than males. In 2022, the gender-specific diagnosed prevalent cases of Alzheimer's disease accounted for around 64% of females and 36% of males in Japan.
• In 2022, the age-specific distribution of the disease suggests that the age cohort of 75-84 years accounted for the majority, nearly 51% of the cases, followed by =85 accounting for 32% of the cases, followed by others in Japan. These cases of Alzheimer's disease are expected to increase during the forecast period.
• According to the publisher's epidemiology model for Alzheimer's disease, in Japan, in 2022, there were approximately 2,324,183 cases of MCI, 826,139 cases of mild dementia, 517,671 cases of moderate dementia, and 286,716 cases of severe dementia, which are expected to increase during the study period.

Scope of the Report

• The report covers a descriptive overview of Alzheimer's disease, explaining its symptoms, pathophysiology, and various diagnostic approaches.
• The report provides insight into the historical and forecasted patient pool of Alzheimer's disease in Japan.
• The report assesses the disease risk and burden of Alzheimer's disease.
• The report helps recognize the growth opportunities concerning the patient population in Japan.
• The report provides the segmentation of the disease epidemiology for Japan, the total diagnosed prevalent cases of Alzheimer's disease, gender-specific diagnosed prevalent cases of Alzheimer's disease, age-specific diagnosed prevalent cases of Alzheimer's Disease, and severity-specific diagnosed prevalent cases of Alzheimer's disease.

Report Highlights

• Ten years Forecast of Alzheimer's Disease
• Japan Coverage
• Total Diagnosed Prevalent Cases of Alzheimer's Disease
• Gender-specific Cases of Alzheimer's Disease
• Age-specific Cases of Alzheimer's Disease
• Severity-specific Cases of Alzheimer's Disease

Key Questions Answered

• What are the disease risks and burdens of Alzheimer's disease?
• What is the historical Alzheimer's disease patient pool in Japan?
• What would be the forecasted patient pool of Alzheimer's disease in Japan?
• What are the growth opportunities concerning the patient population of Alzheimer's disease?
• Which age group would have the highest diagnosed prevalent population of Alzheimer's disease in the forecast period (2023-2032)?
• At what CAGR is the population expected to grow in Japan during the forecast period (2023-2032)?

Reasons to Buy

The Alzheimer's disease report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the Alzheimer's disease epidemiology forecast in Japan.
• The Alzheimer's disease epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Alzheimer's disease epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by Segmentation
• Factors Driving Growth in a Specific Patient Population

Geographies Covered

• Japan

Study Period: 2019-2032